Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.

Wagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR.

Anal Bioanal Chem. 2019 Jan 7. doi: 10.1007/s00216-018-1558-9. [Epub ahead of print]

PMID:
30617391
2.

Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans.

Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):603-612. doi: 10.1002/psp4.12325. Epub 2018 Aug 12.

3.

Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.

Lohy Das JP, Kyaw MP, Nyunt MH, Chit K, Aye KH, Aye MM, Karlsson MO, Bergstrand M, Tarning J.

Malar J. 2018 Mar 23;17(1):126. doi: 10.1186/s12936-018-2278-5.

4.

Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia.

Lohy Das J, Dondorp AM, Nosten F, Phyo AP, Hanpithakpong W, Ringwald P, Lim P, White NJ, Karlsson MO, Bergstrand M, Tarning J.

AAPS J. 2017 Nov;19(6):1842-1854. doi: 10.1208/s12248-017-0141-1. Epub 2017 Sep 11.

PMID:
28895080
5.

An automated sampling importance resampling procedure for estimating parameter uncertainty.

Dosne AG, Bergstrand M, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520. doi: 10.1007/s10928-017-9542-0. Epub 2017 Sep 8.

6.

Model averaging for robust assessment of QT prolongation by concentration-response analysis.

Dosne AG, Bergstrand M, Karlsson MO, Renard D, Heimann G.

Stat Med. 2017 Oct 30;36(24):3844-3857. doi: 10.1002/sim.7395. Epub 2017 Jul 13.

PMID:
28703360
7.

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.

Permala J, Tarning J, Nosten F, White NJ, Karlsson MO, Bergstrand M.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02491-16. doi: 10.1128/AAC.02491-16. Print 2017 May.

8.

In Vitro and In Vivo Modeling of Hydroxypropyl Methylcellulose (HPMC) Matrix Tablet Erosion Under Fasting and Postprandial Status.

Guiastrennec B, Söderlind E, Richardson S, Peric A, Bergstrand M.

Pharm Res. 2017 Apr;34(4):847-859. doi: 10.1007/s11095-017-2113-7. Epub 2017 Feb 2.

9.

Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.

Röshammar D, Bergstrand M, Andersson T, Storey RF, Hamrén B.

Int J Clin Pharmacol Ther. 2017 May;55(5):416-424. doi: 10.5414/CP202748.

PMID:
28139972
10.

Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.

Guiastrennec B, Sonne DP, Hansen M, Bagger JI, Lund A, Rehfeld JF, Alskär O, Karlsson MO, Vilsbøll T, Knop FK, Bergstrand M.

CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):692-700. doi: 10.1002/psp4.12152.

11.

Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling.

Dosne AG, Bergstrand M, Harling K, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):583-596. Epub 2016 Oct 11.

12.

Maintaining knife sharpness in industrial meat cutting: A matter of knife or meat cutter ability.

Karltun J, Vogel K, Bergstrand M, Eklund J.

Appl Ergon. 2016 Sep;56:92-100. doi: 10.1016/j.apergo.2016.03.010. Epub 2016 Apr 6.

PMID:
27184316
13.
14.

A strategy for residual error modeling incorporating scedasticity of variance and distribution shape.

Dosne AG, Bergstrand M, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2016 Apr;43(2):137-51. doi: 10.1007/s10928-015-9460-y. Epub 2015 Dec 17.

15.

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions.

Hénin E, Bergstrand M, Weitschies W, Karlsson MO.

Pharm Res. 2016 Mar;33(3):751-62. doi: 10.1007/s11095-015-1824-x. Epub 2015 Nov 9.

PMID:
26553354
16.

Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention.

Bergstrand M, Nosten F, Lwin KM, Karlsson MO, White NJ, Tarning J.

Sci Transl Med. 2014 Oct 29;6(260):260ra147. doi: 10.1126/scitranslmed.3005311. Epub 2014 Oct 29.

17.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J.

Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Review.

PMID:
24060672
18.

Comparisons of Analysis Methods for Proof-of-Concept Trials.

Karlsson KE, Vong C, Bergstrand M, Jonsson EN, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2013 Jan 16;2:e23. doi: 10.1038/psp.2012.24.

19.

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.

Rekić D, Röshammar D, Bergstrand M, Tarning J, Calcagno A, D'Avolio A, Ormaasen V, Vigan M, Barrail-Tran A, Ashton M, Gisslén M, Äbelö A.

AAPS J. 2013 Apr;15(2):308-15. doi: 10.1208/s12248-012-9440-8. Epub 2012 Dec 7.

20.

Letter to the editor regarding: "a reduction in between subject variability is not mandatory for selecting a new covariate".

Karlsson MO, Bergstrand M.

J Pharmacokinet Pharmacodyn. 2012 Dec;39(6):725-6; author reply 727. doi: 10.1007/s10928-012-9273-1. Epub 2012 Sep 30. No abstract available.

PMID:
23054250
21.

Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.

Tarning J, Chotsiri P, Jullien V, Rijken MJ, Bergstrand M, Cammas M, McGready R, Singhasivanon P, Day NP, White NJ, Nosten F, Lindegardh N.

Antimicrob Agents Chemother. 2012 Nov;56(11):5764-73. doi: 10.1128/AAC.01242-12. Epub 2012 Aug 27.

22.

Serial correlation in optimal design for nonlinear mixed effects models.

Nyberg J, Höglund R, Bergstrand M, Karlsson MO, Hooker AC.

J Pharmacokinet Pharmacodyn. 2012 Jun;39(3):239-49. doi: 10.1007/s10928-012-9245-5. Epub 2012 Mar 14.

PMID:
22415637
23.

Rapid sample size calculations for a defined likelihood ratio test-based power in mixed-effects models.

Vong C, Bergstrand M, Nyberg J, Karlsson MO.

AAPS J. 2012 Jun;14(2):176-86. doi: 10.1208/s12248-012-9327-8. Epub 2012 Feb 17.

24.

A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Hénin E, Bergstrand M, Standing JF, Karlsson MO.

AAPS J. 2012 Jun;14(2):155-63. doi: 10.1208/s12248-012-9324-y.

25.

Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance.

Wallin JE, Bergstrand M, Wilczek HE, Nydert PS, Karlsson MO, Staatz CE.

Ther Drug Monit. 2011 Dec;33(6):663-72. doi: 10.1097/FTD.0b013e31823415cc.

PMID:
22105583
26.

A semi-mechanistic modeling strategy to link in vitro and in vivo drug release for modified release formulations.

Bergstrand M, Söderlind E, Eriksson UG, Weitschies W, Karlsson MO.

Pharm Res. 2012 Mar;29(3):695-706. doi: 10.1007/s11095-011-0594-3. Epub 2011 Sep 27.

PMID:
21948457
27.

A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.

Bergstrand M, Söderlind E, Eriksson UG, Weitschies W, Karlsson MO.

Pharm Res. 2012 Feb;29(2):574-84. doi: 10.1007/s11095-011-0595-2. Epub 2011 Sep 23.

PMID:
21948384
28.

Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.

Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G.

Clin Cancer Res. 2011 Nov 1;17(21):6867-77. doi: 10.1158/1078-0432.CCR-11-0074. Epub 2011 Sep 14.

29.

Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models.

Bergstrand M, Hooker AC, Wallin JE, Karlsson MO.

AAPS J. 2011 Jun;13(2):143-51. doi: 10.1208/s12248-011-9255-z. Epub 2011 Feb 8.

30.

Handling data below the limit of quantification in mixed effect models.

Bergstrand M, Karlsson MO.

AAPS J. 2009 Jun;11(2):371-80. doi: 10.1208/s12248-009-9112-5. Epub 2009 May 19.

31.

Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics.

Bergstrand M, Söderlind E, Weitschies W, Karlsson MO.

Clin Pharmacol Ther. 2009 Jul;86(1):77-83. doi: 10.1038/clpt.2009.43. Epub 2009 Apr 22.

PMID:
19387437
32.

Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole.

Edsbäcker S, Larsson P, Bergstrand M.

Aliment Pharmacol Ther. 2003 Feb;17(3):403-8.

33.

Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.

Lundin PD, Edsbäcker S, Bergstrand M, Ejderhamn J, Linander H, Högberg L, Persson T, Escher JC, Lindquist B.

Aliment Pharmacol Ther. 2003 Jan;17(1):85-92.

34.

Enzyme purification by genetically attached polycysteine and polyphenylalanine affinity tails.

Persson M, Bergstrand MG, Bülow L, Mosbach K.

Anal Biochem. 1988 Aug 1;172(2):330-7.

PMID:
3142291

Supplemental Content

Loading ...
Support Center